In addition, 50% suppression of CCR1 expression has been used as a pharmacodynamic (PD) marker of BET inhibition in clinical trials, where it was associated with clinical response in patients with relapsed or refractory lymphoma (8). This evidence concerns the gene DNER and lymphoma.